Security
MLTX · MoonLake Immunotherapeutics
MLTXNASDAQCommon stockCurrentCIK 1821586Updated Sep 27, 2026
Name history
Helix Acquisition Corp · through Mar 31, 2022
MLTX price & chart
Loading TradingView…
NASDAQ:MLTX on TradingView ↗In the news
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering ↗
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action News provided by Hagens Berman Sobol Shapiro LLP Dec 15, 2025, 13:01 ET Share this article Share to X Share this article Share to X SAN FRANCISCO , Dec. 15, 2025 /PRNewsw ↗
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More News provided by The Gross Law Firm Dec 15, 2025, 09:00 ET Share this article Share to X Share this article Share to X NEW YORK , Dec. 15, 2025 /PRNewswire/ -- The ↗
Recent filings
Show 5 more recent filings
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Other Events
Items 8.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
424B5 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 424,433,000Source | 477,933,282Source | 526,540,115Source | 76,843,301Source |
| Property, Plant and Equipment, NetUSD | 577,000Source | 722,226Source | 320,865Source | 49,389Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 334,517,000Source | 180,426,449Source | 451,169,337Source | 39,505,627Source |
| Assets, CurrentUSD | 421,694,000Source | 474,288,845Source | 514,167,302Source | 76,511,332Source |
| Operating Lease, Right-of-Use AssetUSD | 1,566,000Source | 2,922,211Source | 3,628,480Source | 282,580Source |
| Other Assets, NoncurrentUSD | 596,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 119,952,000Source | 24,542,143Source | 13,049,096Source | 8,076,603Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 766,781,000Source | 677,414,830Source | 609,969,236Source | 129,192,291Source |
| Retained Earnings (Accumulated Deficit)USD | -462,911,000Source | -235,592,989Source | -116,657,472Source | -80,650,212Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 604,000Source | 4,996,769Source | 2,357,621Source | 350,946Source |
| Stockholders' Equity Attributable to ParentUSD | 304,481,000Source | 446,825,002Source | 495,675,683Source | 48,898,296Source |
| Liabilities and EquityUSD | 424,433,000Source | 477,933,282Source | 526,540,115Source | 76,843,301Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 45,478,000Source | 22,463,861Source | 9,965,680Source | 7,665,446Source |
| Operating Lease, Liability, CurrentUSD | 1,234,000Source | 1,371,962Source | 1,197,876Source | 153,629Source |
| Operating Lease, Liability, NoncurrentUSD | 374,000Source | 1,457,598Source | 2,499,990Source | 128,951Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 0Source | 6,566,137Source | 17,815,336Source | 19,868,402Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | 74,100,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -230,321,000Source | -121,244,400Source | -44,079,117Source | -64,506,051Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,616,000Source | 1,384,729Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 12,898,000Source | 7,281,596Source | 7,106,005Source | 9,654,778Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 20,560,000Source | 7,154,795Source | 1,582,712Source | -1,314,318Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -196,007,000Source | -116,587,263Source | -42,778,167Source | -55,893,900Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 202,992,000Source | -205,595,299Source | -25,184,324Source | -32,340,593Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 35,000Source | 519,520Source | 284,634Source | 16,009Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | 50Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 145,997,000Source | 51,311,708Source | 479,701,508Source | 119,692,735Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 154,091,000Source | -270,742,888Source | 411,663,710Source | 31,466,782Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 334,517,000Source | 180,426,449Source | 451,169,337Source | 39,505,627Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,059,000Source | — | — | — |
| Income Taxes Paid, NetUSD | 799,000Source | 147,294Source | 41,713Source | 4,312Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 12,898,000Source | 7,281,596Source | 7,106,005Source | 9,654,778Source |
| DepreciationUSD | — | — | 13,158Source | 12,358Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 599,000Source | -42,186Source | 151,493Source | 325,317Source |
| General and Administrative ExpenseUSD | 41,972,000Source | 30,319,780Source | 22,321,216Source | 23,012,463Source |
| Income Tax Expense (Benefit)USD | 611,000Source | 282,199Source | 94,388Source | 36,366Source |
| InterestExpenseNonoperatingUSD | 7,248,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -227,318,000Source | -118,935,517Source | -36,007,260Source | -49,973,249Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -3,003,000Source | -2,308,883Source | -8,071,857Source | -14,532,802Source |
| Operating ExpensesUSD | 244,834,000Source | 143,091,082Source | 54,123,096Source | 65,061,417Source |
| Operating Lease, ExpenseUSD | — | — | 399,882Source | 155,552Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 591,732Source |
| Pension Expense (Reversal of Expense), NoncashUSD | -58,000Source | 1,300Source | -85,254Source | 304,031Source |
| Proceeds from Issuance of Long-term DebtUSD | 73,022,000Source | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 468,401,000Source | 145,202,997Source | 150,833,021Source | 9,901,437Source |
| Proceeds from Stock Options ExercisedUSD | — | 242,004Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -244,834,000Source | -143,091,082Source | -54,123,096Source | -65,061,417Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 591,732Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -229,710,000Source | -120,962,201Source | -43,984,729Source | -64,469,685Source |
| Income Tax Expense (Benefit)USD | 611,000Source | 282,199Source | 94,388Source | 36,366Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -3,003,000Source | -2,308,883Source | -8,071,857Source | -14,532,802Source |
| Net Income (Loss) Attributable to ParentUSD | -227,318,000Source | -118,935,517Source | -36,007,260Source | -49,973,249Source |
| Earnings Per Share, BasicUSD per share | -3.53Source | -1.89Source | -0.73Source | -1.7Source |
| Earnings Per Share, DilutedUSD per share | -3.53Source | -1.89Source | -0.73Source | -1.7Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 64,463,889Source | 62,870,237Source | 49,122,534Source | 29,361,353Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 64,463,889Source | 62,870,237Source | 49,122,534Source | 29,361,353Source |
| Interest Expense (non-operating)USD | 7,248,000Source | — | — | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 599,000Source | -42,186Source | 151,493Source | 325,317Source |
| General and Administrative ExpenseUSD | 41,972,000Source | 30,319,780Source | 22,321,216Source | 23,012,463Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -229,118,000Source | -120,417,158Source | -43,469,946Source | -62,115,251Source |
| Operating ExpensesUSD | 244,834,000Source | 143,091,082Source | 54,123,096Source | 65,061,417Source |
| Operating Lease, ExpenseUSD | — | — | 399,882Source | 155,552Source |
| Research and Development ExpenseUSD | 202,862,000Source | 112,771,302Source | 31,801,880Source | 42,048,954Source |
Filing attachments
ea030119101ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ea030119101ex99-1.htm PRESS RELEASE, DATED AUGUST 10, 2026 Exhibit 99.1 MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% …
Read attachment ↗ea029576601ex4-1.htm · 8-K · 2026-06-25
EX-4.1 3 ea029576601ex4-1.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.1 MOONLAKE IMMUNOTHERAPEUTICS PRE-FUNDED WARRANT TO PURCHASE CLASS A ORDINARY SHARES Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: June 25, 2026 ─────────────────────────────────────────────────────────── MoonLake Immunotherapeutics, a Cayman Islands exempted company (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of whi…
Read attachment ↗ea029539901ex99-1.htm · 8-K · 2026-06-22
EX-99.1 2 ea029539901ex99-1.htm PRESS RELEASE, DATED JUNE 21, 2026 Exhibit 99.1 MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than th…
Read attachment ↗ea029539901ex99-2.htm · 8-K · 2026-06-22
EX-99.2 3 ea029539901ex99-2.htm SLIDE PRESENTATION, DATED JUNE 22, 2026 Exhibit 99.2 © 2026 | Proprietary | MoonLake TX MoonLake Immunotherapeutics Investor Day June 22nd, 2026 © 2026 | Proprietary | MoonLake TX Source: Welcome to our Investor Day MoonLake Corporate Strategy Agenda Sub-topics Topic Speaker Timing Proposed Label Update on BLA progress BLA strategy Jorge 20 mins Welcome MLTX & SLK summary Introduction Jorge 10 mins Final Week 52 Phase 3 VELA data Update on VELA-TEEN data Fin…
Read attachment ↗